Leerink Partners Maintains a Hold on Amgen (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best affordable growth stocks to buy. Leerink Partners analyst David Risinger maintained their neutral stance on Amgen Inc. (NASDAQ:AMGN) on August 26, giving the stock a Hold rating.

Dogs of the Dow: Why Amgen’s (AMGN) Dividend Power Makes it a Standout Pick

The analyst told investors in a research note that he expects the recent approval of Repatha’s expanded label to boost its market penetration, especially in the primary prevention space for cardiovascular events.

However, he added that the current market penetration remains low despite this positive development, with the immediate opportunity depending more on the rising treatment urgency instead of expansion in the patient base.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.